

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

March 29, 2022

Jaume Pons, Ph.D. Chief Executive Officer ALX Oncology Holdings, Inc. 323 Allerton Avenue South San Francisco, CA 94080

> Re: ALX Oncology Holdings, Inc. Registration Statement on Form S-3 Filed March 25, 2022 File No. 333-263863

Dear Mr. Pons:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Michael Coke, Esq.